We've found
4,191
archived clinical trials in
Constipation
We've found
4,191
archived clinical trials in
Constipation
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Updated: 2/11/2016
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 2/11/2016
Click here to add this to my saved trials
Safety and Health Intervention Project
Updated: 2/13/2016
Developing a Prescription Opioid Overdose Prevention Intervention in Addictions Treatment
Status: Enrolling
Updated: 2/13/2016
Safety and Health Intervention Project
Updated: 2/13/2016
Developing a Prescription Opioid Overdose Prevention Intervention in Addictions Treatment
Status: Enrolling
Updated: 2/13/2016
Click here to add this to my saved trials
The Effectiveness of Lubiprostone in Constipated Diabetics
Updated: 2/17/2016
A Randomized, Double Blind, Placebo-controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients
Status: Enrolling
Updated: 2/17/2016
The Effectiveness of Lubiprostone in Constipated Diabetics
Updated: 2/17/2016
A Randomized, Double Blind, Placebo-controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients
Status: Enrolling
Updated: 2/17/2016
Click here to add this to my saved trials
The Effectiveness of Lubiprostone in Constipated Diabetics
Updated: 2/17/2016
A Randomized, Double Blind, Placebo-controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients
Status: Enrolling
Updated: 2/17/2016
The Effectiveness of Lubiprostone in Constipated Diabetics
Updated: 2/17/2016
A Randomized, Double Blind, Placebo-controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients
Status: Enrolling
Updated: 2/17/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Updated: 3/2/2016
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients
Updated: 3/2/2016
The Effects of Tegaserod on Orocecal Transit in Elderly Patients With Chronic Constipation
Status: Enrolling
Updated: 3/2/2016
Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients
Updated: 3/2/2016
The Effects of Tegaserod on Orocecal Transit in Elderly Patients With Chronic Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients
Updated: 3/2/2016
The Effects of Tegaserod on Orocecal Transit in Elderly Patients With Chronic Constipation
Status: Enrolling
Updated: 3/2/2016
Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients
Updated: 3/2/2016
The Effects of Tegaserod on Orocecal Transit in Elderly Patients With Chronic Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients
Updated: 3/2/2016
The Effects of Tegaserod on Orocecal Transit in Elderly Patients With Chronic Constipation
Status: Enrolling
Updated: 3/2/2016
Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients
Updated: 3/2/2016
The Effects of Tegaserod on Orocecal Transit in Elderly Patients With Chronic Constipation
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Updated: 3/22/2016
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials